The era of in vivo T cell engineering

Gustavo Campos Ramos,Michael Hudecek

DOI: https://doi.org/10.1016/j.medj.2022.01.012

2022-02-11

Med

Abstract:Cell therapy with genetically engineered T cells has revolutionized the treatment of malignant diseases, but its potential use beyond the realms of oncology has been underexplored. In a recent study, Rurik et al.1 built on the technologies underlying mRNA vaccines to transduce T cells in vivo, harnessing them to target cardiac fibrosis.